Article
Spotlight on gefitinib in non-small-cell lung cancer.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice - 1 Jan 2005
Frampton James E, Easthope Stephanie E
Abstract excerpt
Gefitinib (Iressa), the first commercially available epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor, is indicated in the management of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC). However, approved uses differ between countries; in most markets, gefitinib is approved for third-line use only (e.g. the US, Canada and Switzerland), although in some it is...
Topics
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Gefitinib
- Humans
- Lung Neoplasms
- Mutation
- Protein Kinase Inhibitors
- Quinazolines
- Treatment Outcome